{"id":4038,"date":"2023-01-04T06:30:30","date_gmt":"2023-01-04T11:30:30","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\/"},"modified":"2026-09-24T00:07:00","modified_gmt":"2026-09-24T04:07:00","slug":"gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2023\/01\/04\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\/","title":{"rendered":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors des prochaines conf\u00e9rences investisseurs"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Paris, France, January 4, 2023, 7:30 am CET<\/strong> \u2013 GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company will participate in the following investor conferences in January 2023:<\/p>\n\n<p class=\"wp-block-paragraph\">\u00a0<\/p>\n\n<p class=\"wp-block-paragraph\"><strong><u>26<sup>th<\/sup> ODDO BHF Forum<\/u><\/strong><\/p>\n\n<p class=\"wp-block-paragraph\"><em>January 9 &#8211; 10, 2023 &#8211; Virtual <\/em><\/p>\n\n<p class=\"wp-block-paragraph\"><strong>Bernard Gilly<\/strong>, Co-Founder &amp; Chief Executive Officer, and <strong>Thomas Gidoin<\/strong>, Chief Financial Officer, will host investor meetings.<\/p>\n\n<p class=\"wp-block-paragraph\">\u00a0<\/p>\n\n<p class=\"wp-block-paragraph\"><strong><u>Invest Securities Biomed Forum<\/u><\/strong><\/p>\n\n<p class=\"wp-block-paragraph\"><em>January 24, 2023 &#8211; Paris, France<\/em><\/p>\n\n<p class=\"wp-block-paragraph\"><strong>Thomas Gidoin<\/strong>, Chief Financial Officer, will attend in person and host investor meetings.<\/p>\n\n<p class=\"wp-block-paragraph\">\u00a0<\/p>\n\n<p class=\"wp-block-paragraph\"><strong><u>11<sup>th<\/sup> Degroof Petercam Healthcare Conference<\/u><\/strong><\/p>\n\n<p class=\"wp-block-paragraph\"><em>January 25, 2023 &#8211; Virtual<\/em><\/p>\n\n<p class=\"wp-block-paragraph\"><strong>Thomas Gidoin<\/strong>, Chief Financial Officer, will host investor meetings.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, January 4, 2023, 7:30 am CET \u2013 GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company will participate in the following investor conferences in January 2023: \u00a0 26th ODDO [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[79],"news-type":[76],"post-year":[],"class_list":["post-4038","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-company-and-personnel","news-type-corporate"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors des prochaines conf\u00e9rences investisseurs - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2023\/01\/04\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors des prochaines conf\u00e9rences investisseurs - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, January 4, 2023, 7:30 am CET \u2013 GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company will participate in the following investor conferences in January 2023: \u00a0 26th ODDO [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2023\/01\/04\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-04T11:30:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:07:00+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/01\\\/04\\\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/01\\\/04\\\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors des prochaines conf\u00e9rences investisseurs\",\"datePublished\":\"2023-01-04T11:30:30+00:00\",\"dateModified\":\"2026-09-24T04:07:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/01\\\/04\\\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\\\/\"},\"wordCount\":122,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/01\\\/04\\\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/01\\\/04\\\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\\\/\",\"name\":\"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors des prochaines conf\u00e9rences investisseurs - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2023-01-04T11:30:30+00:00\",\"dateModified\":\"2026-09-24T04:07:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/01\\\/04\\\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/01\\\/04\\\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2023\\\/01\\\/04\\\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors des prochaines conf\u00e9rences investisseurs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors des prochaines conf\u00e9rences investisseurs - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2023\/01\/04\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors des prochaines conf\u00e9rences investisseurs - GenSight Biologics","og_description":"Paris, France, January 4, 2023, 7:30 am CET \u2013 GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company will participate in the following investor conferences in January 2023: \u00a0 26th ODDO [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2023\/01\/04\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\/","og_site_name":"GenSight Biologics","article_published_time":"2023-01-04T11:30:30+00:00","article_modified_time":"2026-09-24T04:07:00+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2023\/01\/04\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2023\/01\/04\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors des prochaines conf\u00e9rences investisseurs","datePublished":"2023-01-04T11:30:30+00:00","dateModified":"2026-09-24T04:07:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2023\/01\/04\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\/"},"wordCount":122,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2023\/01\/04\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2023\/01\/04\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\/","name":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors des prochaines conf\u00e9rences investisseurs - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2023-01-04T11:30:30+00:00","dateModified":"2026-09-24T04:07:00+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2023\/01\/04\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2023\/01\/04\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2023\/01\/04\/gensight-biologics-invitee-a-presenter-lors-des-prochaines-conferences-investisseurs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics invit\u00e9e \u00e0 pr\u00e9senter lors des prochaines conf\u00e9rences investisseurs"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4038","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=4038"}],"version-history":[{"count":3,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4038\/revisions"}],"predecessor-version":[{"id":7523,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4038\/revisions\/7523"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=4038"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=4038"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=4038"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=4038"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=4038"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=4038"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=4038"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}